Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
14 Results for "
p47phox
" in MedChemExpress (MCE) Product Catalog:
Products (14)
14 Results for "p47phox" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
DATPT is a 12WLVSKF17 peptide-mimetic molecule. DATPT blocks the SNX9-p47phox interaction in the endosome and suppresses reactive oxygen species and inflammatory cytokine production. DATPT with anti-inflammatory and antibacterial functions has the potential for the research of sepsis .
Cat. No.: HY-P3075
CAS No.: 112540-82-6
Synonyms: pTHrP (1-34)
Target:
PTHR PKA PKC PI3K Akt ERK NADPH Oxidase Reactive Oxygen Species (ROS) TGF-beta/Smad Caspase Apoptosis NO Synthase
Research Areas:
pTH-Related Protein (1-34) (human,mouse,rat) (pTHrP (1-34)) is a parathyroid hormone-related protein fragment. Binding of pTH-Related Protein (1-34) (human,mouse,rat) to PTH1R triggers cAMP/PKA and PKC signaling, PI3K-mediated Akt and ERK1/2 phosphorylation, NADPH oxidase-dependent ROS generation, and TGF-beta1 and p47phox expression. pTH-Related Protein (1-34) (human,mouse,rat) induces fibronectin upregulation, osteoblast differentiation, osteoclastic bone resorption, bone formation, eNOS/NO-mediated vasodilation, and sensitization of type II pneumocytes to ultraviolet-induced apoptosis (apoptosis) via caspase 3. pTH-Related Protein (1-34) (human,mouse,rat) can be used in research on diabetic nephropathy, breast cancer, acute lung injury, humoral hypercalcemia of malignancy, osteoporosis, and cartilage degeneration .
Target:
Research Areas:
NOX2-IN-2 diTFA (compound 33) is a potent NOX2 inhibitor targeting the p47phox-p22phox protein-protein interaction with a Ki of 0.24 μM. NOX2-IN-2 diTFA inhibits ROS production derived from NOX2 in cells .
Cat. No.: HY-156425
CAS No.: 2648709-79-7
Target:
Research Areas:
NOX2-IN-2 (compound 33) is a potent NOX2 inhibitor targeting the p47phox-p22phox protein-protein interaction with a Ki of 0.24 μM. NOX2-IN-2 inhibits ROS production derived from NOX2 in cells .
Cat. No.: HY-156424
CAS No.: 2648709-25-3
Target:
Research Areas:
NOX2-IN-1 (compound 10) is an inhibitor of nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2). NOX2-IN-1 targets the p47phox p22phox protein protein interaction with favorable binding affinities and cellular activities .
Cat. No.: HY-RS20305
Target:
Research Areas:
Ncf1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ncf1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P70290
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NCF1; NADPH Oxidase Organizer 2; Neutrophil Cytosolic Factor 1; Nox-Organizing Protein 2; SH3PXD1A; Nox Organizer 2; NOXO2; P47-Phox; p47phox; NCF-47K; NCF1A; NCF-1; 47 KDa Autosomal Chronic Granulomatous Disease Protein; Neutrophil Cytosolic Factor 1 (47
Species:
Human
Source:
E. coli
Cat. No.: HY-RS09077
Target:
Research Areas:
NCF1 Human Pre-designed siRNA Set A contains three designed siRNAs for NCF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS26813
Target:
Research Areas:
Ncf1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ncf1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
